Email this article 
Post a Comment Comparative assessment of the quality of life in patients with bronchial asthma and chronic obstructive pulmonary disease before and after COVID-19
- Authors: Svist P.G.1, Torchinsky N.V.1, Avdeev S.N.1, Briko N.I.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 41, No 5 (2024)
- Pages: 19-26
- Section: Original studies
- URL: https://journals.rcsi.science/PMJ/article/view/271975
- DOI: https://doi.org/10.17816/pmj41519-26
- ID: 271975
Cite item
Abstract
Objective. To compare the quality of life of patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) before and after COVID-19.
Materials and methods. 73 patients diagnosed with bronchial asthma and 78 patients with COPD who were treated at Sechenov University Clinical Hospital №4, participated in the retrospective dynamic comparative study based on the principle «from cause to effect». Assessment of the quality of the patients` life was carried out before and after COVID-19 using a visual analogue scale from 0 to 100 points and the universal EuroQol-5D questionnaire. Mobility, self-care abilities, habitual activity, severity of pain/discomfort, the presence of anxiety/depression in the post-COVID period were assessed.
Results. In patients with COPD before COVID-19, the average total score on the visual–analogue scale was 89,5 [83,8; 95], and after COVID-19 it was 70 [64,5; 80] points. In the post-covid period, 91 % of people with COPD noted some mobility limitations, 33.3 % experienced difficulties with self-care, 65.4 % of patients could not engage in habitual activities, 60.3 % suffered pronounced pain or discomfort, and 29.5 % of patients had severe anxiety or depression. In patients with asthma before COVID-19, the average total score was 90 [88,4; 91] points, and after COVID-19 it was 75 [70,2; 80,2]. In the post-ovarian period, mobility limitations were noted by 71.2 % of patients, and 64.4 % had difficulties with taking care of themselves, 54.8 % could not engage in habitual activities. At the same time, 78.1 % of patients experienced pain or discomfort, and 58.9 % had moderate anxiety or depression.
Conclusions. COVID-19 has led to a significant decrease in the quality of life in patients with asthma and COPD. This may be associated with a worsening of the course of the disease and increase in the number of exacerbations of these pulmonary pathologies, resulting in significant limitation of mobility, growing pain or discomfort, as well as the occurrence of severe anxiety or depression.
Full Text
##article.viewOnOriginalSite##About the authors
Polina G. Svist
I.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: polina_svt@mail.ru
ORCID iD: 0000-0003-2239-0946
SPIN-code: 5939-9351
Postgraduate Student of the Department of Epidemiology and Evidence-based Medicine, Institute of Public Health named after F.F. Erisman
Russian Federation, MoscowN. V. Torchinsky
I.M. Sechenov First Moscow State Medical University
Email: torchinsky75@mail.ru
ORCID iD: 0000-0003-3835-0842
PhD (Medicine), Associate Professor of the Department of Epidemiology and Evidence-based Medicine , Institute of Public Health named after F.F. Erisman
Russian Federation, MoscowSergey N. Avdeev
I.M. Sechenov First Moscow State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-5999-2150
DSc (Medicine), Professor, Academician of the Russian Academy of Sciences, Head of Department of Pulmonology, Institute of Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, MoscowN. I. Briko
I.M. Sechenov First Moscow State Medical University
Email: nbrico@mail.ru
ORCID iD: 0000-0002-6446-2744
DSc (Medicine), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Epidemiology and Evidence-Based Medicine , Institute of Public Health named after F.F. Erisman
Russian Federation, MoscowReferences
- Leung J.M., Yang C.X., Tam A., Shaipanich T. Hackett T.L., Singhera G.K., Dorscheid D.R., Sin D.D. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 2020; 55 (5): 2000688. doi: 10.1183/13993003.00688-2020
- Аlqahtani J.S., Oyelade T., Aldhahir A.M., Alghamdi S.M. Almehmadi M., Alqahtani A.S., Quaderi S., Mandal S., Hurst J.R. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020; 15 (5): e0233147. DOI: 10.1371/ journal.pone.0233147
- Pardhan S., Wood S., Vaughan M., Trott M. The risk of COVID-19 related hospitalsation, intensive care unit admission and mortality in people with underlying asthma or COPD: a systematic review and meta-analysis. Front. Med. (Lausanne). 2021; 8: 668808. doi: 10.3389/fmed.2021.668808
- Rajabi H., Mortazavi D., Konyalilar N., Aksoy G.T., Erkan S., Korkunc S.K., Kayalar O., Bayram H., Rahbarghazi R. Forthcoming complications in recovered COVID-19 patients with COPD and asthma; possible therapeutic opportunities. Cell Commun. Signal. 2022; 20 (1): 173. doi: 10.1186/s12964-022-00982-5
- Алекперов Р.И., Макарьянц Н.Н., Чушкин М.И., Абубикиров А.Ф., Кудрявцева Э.З., Абдуллаев Р.Ю. Особенности течения хронической обструктивной болезни легких у пациентов, перенесших COVID-19. Доктор.Ру. 2024; 23 (1): 7–14. doi: 10.31550/1727-2378-2024-23-1-7-14 / Alekperov R.I., Makaryants N.N., Chushkin M.I., Abubikirov A.F., Kudryavtseva E.Z., Abdullayev R.Yu. Chronic obstructive pulmonary disease in post-COVID-19 patients. Doctor.Ru. 2024; 23 (1): 7–14 (in Russian). doi: 10.31550/1727-2378-2024-23-1-7-14
- Zhang J.J., Dong X., Cao Y.Y., Yuan Y.D., Yang Y.B., Yan YQ, Akdis C.A., Gao Y.D. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75 (7): 1730–1741. doi: 10.1111/all.14238
- Lombardi C., Gani F., Berti A., Comberiati P., Peroni D., Cottini M. Asthma and COVID-19: a dangerous liaison? Asthma Res Pract. 2021; 7 (1): 9. doi: 10.1186/s40733-021-00075-z
- Muntean I.A., Leru P.M., Pintea I., Bocsan I.C., Dobrican C.T., Deleanu D.A. A retrospective study regarding the influence of COVID-19 disease on asthma. BMC Pulm Med. 2023; 23 (1): 22. doi: 10.1186/s12890-023-02309-7
- Kwok W.C., Tam T.C.C., Lam D.C.L., Leung J.K.C., Chan K.P.F., Chan S.K.S., Chiang K.Y., Ip M.S.M., Ho J.C.M. Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong. Respir Res. 2023; 24 (1): 53. doi: 10.1186/s12931-023-02363-z
- Мусина Н.З., Федяева В.К. Методы расчета QALY как интегрального показателя эффективности в процессе комплексной оценки лекарственных препаратов. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2017; 1 (10): 66–71. doi: 10.17749/2070-4909.2017.10.1.066-071 / Musina N.Z., Fedyaeva V.K. The use of QALY as an integral measure of effectiveness in the evaluation of medical technologies. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya 2017; 1 (10): 66–71 (in Russian). doi: 10.17749/2070-4909.2017.10.1.066-071
- Janssen M.F., Pickard A.S., Golicki D., Gudex C., Niewada M., Scalone L., Swinburn P., Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013; 22 (7): 1717–27. doi: 10.1007/s11136-012-0322-4
- Devlin N., Parkin D., Janssen B. Methods for Analysing and Reporting EQ-5D Data. Cham (CH): Springer 2020. PMID: 33347096
- Hernandez G., Garin O., Dima A.L., Pont A., Martí Pastor M., Alonso J., Van Ganse E., Laforest L., de Bruin M., Mayoral K., Serra-Sutton V., Ferrer M.; ASTRO-LAB Group. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study. J Med Internet Res. 2019; 21 (1): e10178 doi: 10.2196/10178
- Hurst J.R., Skolnik N., Hansen G.J., Anzueto A., Donaldson G.C., Dransfield M.T., Varghese P. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. Eur J Intern Med. 2020; 73: 1–6. doi: 10.1016/j.ejim.2019.12.014
Supplementary files
